Might Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) finally be bought?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the first patient has been treated in its OPTIC (Optimizing PonatinibTreatment In CML) trial of Iclusig® (ponatinib).
In a research report released yesterday, J.P.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the second quarter of 2015, including revenue from sales of Iclusig® (ponatinib).
Gilead Sciences, Inc. (NASDAQ:GILD) shares spiked more than 4% in pre-market after the biopharmaceutical company beat estimates in its quarterly earnings.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional …
Second quarter earnings season is upon us and Cowen & Co. is counting on the biotechnology sector to deliver.
Biotechnology companies release data on pipeline drug studies up update analysts and investors on the progress of a drug. Positive data releases have …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated …
William Blair analyst Y Katherine Xu came out with a favorable report on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), after the company announced updated clinical data on its investigational …
